Sponsor Pipeline

Qi deng Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
0
Recruiting
1
Disease Areas
Active Trials by Phase
Phase 1
3
Early Phase 1
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT07383233 CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute… Lymphoma Not Yet Recruiting
NCT07538713 Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute… CAR T Cell Therapy Not Yet Recruiting
NCT07574073 CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory… Anti-CD20 Monoclonal Antibody Not Yet Recruiting
Early Phase 1
NCT07365059 Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell… Plasma Cell Dyscrasias Not Yet Recruiting
Not specified
NCT07008872 CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute… CD7+ Lymphoma Not Yet Recruiting
Disease Areas
Get alerts when Qi deng's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free